{"gene":"SGCG","run_date":"2026-06-14T21:19:36+00:00","timeline":{"discoveries":[{"year":1995,"finding":"Mutations in gamma-sarcoglycan (SGCG) not only abolish gamma-sarcoglycan but also disrupt the integrity of the entire sarcoglycan complex, establishing that gamma-sarcoglycan is required for complex integrity.","method":"Genetic mapping and mutation analysis in SCARMD patients combined with protein complex assessment","journal":"Science","confidence":"High","confidence_rationale":"Tier 2 / Strong — foundational genetic and biochemical finding replicated across multiple subsequent studies","pmids":["7481775"],"is_preprint":false},{"year":1996,"finding":"Frameshifting mutations disrupting the distal carboxyl-terminus of gamma-sarcoglycan result in complete absence of both gamma- and beta-sarcoglycan, demonstrating that the C-terminal region (which contains EGF-like cysteine-rich sequences) is essential for stability of the sarcoglycan complex.","method":"Mutation analysis of patient muscle biopsies combined with immunostaining for sarcoglycan subunits","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic/biochemical evidence from multiple patients, single lab","pmids":["8923014"],"is_preprint":false},{"year":1996,"finding":"Alpha-, beta-, and gamma-sarcoglycan constitute a tightly associated sarcolemmal complex that cannot be disrupted by SDS treatment, demonstrating their strong biochemical interdependence at the sarcolemma.","method":"Immunofluorescence, Western blotting, and SDS-resistance co-fractionation of the dystrophin-glycoprotein complex from skeletal muscle","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct biochemical fractionation in patient and control muscle, single lab","pmids":["8641426"],"is_preprint":false},{"year":1998,"finding":"Genetic knockout of gamma-sarcoglycan in mice causes secondary reduction of beta- and delta-sarcoglycan with partial retention of alpha- and epsilon-sarcoglycan, indicating that beta-, gamma-, and delta-sarcoglycan function as a unit. Membrane disruptions and apoptosis occurred independently of dystrophin loss, demonstrating that sarcoglycan loss is itself sufficient to cause membrane defects.","method":"Homologous recombination knockout mouse; Evans blue dye vital staining; immunofluorescence; TUNEL apoptosis assay","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO with multiple orthogonal readouts, widely replicated","pmids":["9732288"],"is_preprint":false},{"year":2000,"finding":"Gamma-sarcoglycan is expressed in smooth muscle and associates with epsilon-, beta-, and delta-sarcoglycans and sarcospan to form the smooth muscle sarcoglycan-sarcospan complex, distinct from the striated muscle complex.","method":"Immunoblotting, co-immunoprecipitation/biochemical analysis of smooth muscle membranes, smooth muscle cell culture, and analysis of animal models and a patient with gamma-sarcoglycanopathy","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — biochemical co-fractionation and patient tissue analysis, single lab, multiple orthogonal methods","pmids":["10993904"],"is_preprint":false},{"year":2001,"finding":"Overexpression of gamma-sarcoglycan in mouse muscle leads to cytoplasmic aggregates that prevent normal membrane targeting, upregulation of alpha- and beta-sarcoglycan, and severe muscular dystrophy — demonstrating that proper dosage and membrane localization of gamma-sarcoglycan are critical for correct sarcoglycan complex assembly.","method":"Transgenic mouse overexpression under muscle creatine kinase promoter; histology; immunofluorescence; Western blotting","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — transgenic mouse model with multiple readouts, single lab","pmids":["11287429"],"is_preprint":false},{"year":2001,"finding":"The gamma-sarcoglycan promoter contains a basal promoter region and two myogenesis-dependent enhancer regions; A/T-rich and E-box elements in the upstream enhancer are essential for activation after myotube formation, and MyoD acts as a trans-activator of gamma-sarcoglycan transcription.","method":"Reporter gene constructs with promoter deletions in C2C12 cells; co-transfection with MyoD expression vectors in 10T1/2 fibroblasts; electrophoretic mobility shift assay for binding protein identification","journal":"European journal of biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — promoter deletion and co-transfection assays, single lab, multiple constructs tested","pmids":["11179961"],"is_preprint":false},{"year":2001,"finding":"Delta- and gamma-sarcoglycans localize not only to the sarcolemma but also to the sarcoplasmic reticulum in skeletal muscle: delta-sarcoglycan is found in terminal cisternae, while gamma-sarcoglycan is found in both terminal cisternae and longitudinal SR over I-bands, suggesting functions independent of the dystrophin complex in the SR.","method":"Confocal microscopy and immunoelectron microscopy with subcellular marker co-labeling in rat and mouse skeletal muscle","journal":"The journal of histochemistry and cytochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — immunoelectron microscopy with co-localization controls, single lab","pmids":["11259456"],"is_preprint":false},{"year":2006,"finding":"Biglycan physically binds to gamma-sarcoglycan (as well as alpha-sarcoglycan) via distinct sites on its polypeptide core, and is a component of the dystrophin glycoprotein complex isolated from skeletal muscle membranes. In biglycan-null mice, gamma-sarcoglycan expression is selectively reduced at early developmental stages (P14–P21), establishing biglycan as a ligand and developmental regulator of gamma-sarcoglycan.","method":"Ligand blot overlay, co-immunoprecipitation, biglycan-decorin chimeras, biochemical fractionation of skeletal muscle membranes, immunohistochemistry and Western blotting in biglycan-null mice","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP and ligand blot with chimera mapping, single lab, multiple orthogonal methods","pmids":["16883602"],"is_preprint":false},{"year":2006,"finding":"Zeta-sarcoglycan can substitute for gamma-sarcoglycan in forming a sarcoglycan complex (alpha-beta-zeta-delta), demonstrating that gamma-sarcoglycan's structural role in complex formation can be fulfilled by its homolog zeta-sarcoglycan.","method":"Co-transfection of expression vectors for all six sarcoglycans and dystroglycan into CHO cells followed by immunoprecipitation analysis","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-immunoprecipitation in transfected cells with multiple sarcoglycan combinations, single lab","pmids":["16635485"],"is_preprint":false},{"year":2010,"finding":"Tyrosine 6 (Tyr6) in the intracellular domain of gamma-sarcoglycan is not required for sarcolemmal localization, but is required for normal ERK1/2 phosphorylation signaling after eccentric contractions — demonstrating that localization and mechanical signal transduction are molecularly separable functions of gamma-sarcoglycan.","method":"Viral-mediated gene transfer of wild-type and Y6A mutant gamma-sarcoglycan into gsg-/- mouse muscle; immunofluorescence for localization; immunoblotting for ERK1/2 phosphorylation after eccentric contractions","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — site-directed mutagenesis with in vivo functional readout (two orthogonal assays), single lab but rigorous","pmids":["20371873"],"is_preprint":false},{"year":2014,"finding":"Loss of gamma-sarcoglycan elevates basal p70S6K activation in skeletal muscle in a calcium-independent manner and causes sustained (rather than transient) p70S6K activation after stretch; rapamycin blocks p70S6K but cannot normalize downstream S6RP phosphorylation in gamma-SG-null muscle, indicating gamma-sarcoglycan is required for proper inactivation of the mTOR/p70S6K mechanotransduction pathway.","method":"Cyclic passive stretch of C2C12 myotubes, primary cultures and isolated muscles from C57 and gamma-SG-null mice; immunoblotting for phosphorylated signaling proteins; rapamycin and calcium-chelation pharmacological experiments","journal":"Skeletal muscle","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple cell and tissue preparations with pharmacological validation, single lab","pmids":["25024843"],"is_preprint":false},{"year":2015,"finding":"Gamma-sarcoglycan interacts with the muscle-specific protein archvillin (identified by yeast two-hybrid), and loss of gamma-sarcoglycan causes archvillin upregulation and delocalization at the sarcolemma as well as ablation of the mechanically stimulated archvillin–P-ERK1/2 association, positioning archvillin as a mechanically sensitive signaling component downstream of gamma-sarcoglycan.","method":"Yeast two-hybrid screen; immunofluorescence and Western blotting in gsg-/- and mdx mouse muscle; rAAV rescue experiments; in situ eccentric contractions with P-ERK1/2 nuclear activation analysis; co-immunoprecipitation of archvillin with P-ERK1/2","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — yeast two-hybrid plus multiple orthogonal in vivo validations, single lab","pmids":["25605665"],"is_preprint":false},{"year":2019,"finding":"Full-length recombinant gamma-sarcoglycan (SGCG) was expressed, purified, and subjected to solution NMR spectroscopy in detergent environments, yielding the first NMR spectra of the full-length membrane glycoprotein and providing initial structural characterization.","method":"Recombinant expression in E. coli inclusion bodies using TrpΔLE fusion; chemical cleavage; size-exclusion chromatography; SDS-PAGE; mass spectrometry; 15N-labeled solution NMR spectroscopy","journal":"Protein expression and purification","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — first structural characterization by NMR, single lab, preliminary spectra only","pmids":["31682967"],"is_preprint":false},{"year":2022,"finding":"Proteomic analysis of gamma-sarcoglycan immunoprecipitates from sarcolemmal fractions identified NKCC1 (SLC12A2) as a novel gamma-sarcoglycan complex-associated protein; NKCC1 co-localizes with gamma-sarcoglycan upon co-expression in RH30 cells and co-immunoprecipitates via its cytosolic domains. Pharmacological inhibition of NKCC1 with bumetanide reduces strain-induced ERK1/2 phosphorylation in isolated muscles, linking NKCC1 to gamma-sarcoglycan-dependent mechanosignaling.","method":"LC-MS/MS proteomics of anti-Sgcg immunoprecipitates from enriched sarcolemmal fractions; co-expression and co-immunoprecipitation in RH30 rhabdomyosarcoma cells; immunofluorescence co-localization; bumetanide pharmacological inhibition with ERK1/2 phosphorylation readout in isolated muscles","journal":"Skeletal muscle","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — MS proteomics validated by Co-IP and functional pharmacological experiment, single lab, multiple orthogonal methods","pmids":["35065666"],"is_preprint":false},{"year":2023,"finding":"Gamma-sarcoglycan incorporated into nanodiscs can undergo N-linked glycosylation in vitro by enzymatic transfer of sugar to an asparagine residue, demonstrating that this post-translational modification can be reconstituted in a lipid bilayer environment.","method":"Nanodisc reconstitution with long-chain lipids and membrane scaffold proteins; in vitro N-linked glycosylation assay with oligosaccharyltransferase; SDS-PAGE and mass spectrometry validation","journal":"ACS omega","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — in vitro reconstitution of glycosylation, single lab, first demonstration","pmids":["37929139"],"is_preprint":false},{"year":2010,"finding":"In delta-sarcoglycan knockout mice, gamma-sarcoglycan expression is secondarily reduced in both transverse tubule and sarcoplasmic reticulum membranes, demonstrating that delta-sarcoglycan stabilizes gamma-sarcoglycan in these intracellular membrane compartments.","method":"Immunoblotting of purified TT and SR membrane fractions from wild-type and delta-SG knockout mice","journal":"Cell calcium","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, single method (immunoblotting of fractionated membranes) with no direct interaction experiment for gamma-SG","pmids":["20638123"],"is_preprint":false}],"current_model":"Gamma-sarcoglycan (SGCG) is a transmembrane component of the dystrophin-associated glycoprotein complex that, together with alpha-, beta-, and delta-sarcoglycans, forms a sarcolemmal heterotetrameric complex essential for membrane integrity in skeletal, cardiac, and smooth muscle; loss of gamma-sarcoglycan causes secondary destabilization of the entire sarcoglycan complex, membrane disruptions, apoptosis, and aberrant mechanotransduction signaling (including dysregulated ERK1/2 and mTOR/p70S6K pathways) independently of dystrophin, with its intracellular Tyr6 required for mechanical signal transduction but not for sarcolemmal localization, and its extracellular domain subject to N-linked glycosylation; gamma-sarcoglycan also localizes to the sarcoplasmic reticulum and interacts with biglycan and NKCC1 as extracellular and signaling partners, respectively."},"narrative":{"mechanistic_narrative":"Gamma-sarcoglycan (SGCG) is a transmembrane component of the sarcolemmal sarcoglycan complex whose loss causes limb-girdle muscular dystrophy through destabilization of the complex and direct membrane damage [PMID:7481775, PMID:9732288]. Mutation analysis in patients first established that loss of gamma-sarcoglycan collapses the integrity of the entire sarcoglycan complex, with the cysteine-rich C-terminus being essential for complex stability [PMID:7481775, PMID:8923014]; alpha-, beta-, and gamma-sarcoglycan form a tightly associated, SDS-resistant sarcolemmal unit [PMID:8641426]. Genetic knockout in mice demonstrated that beta-, gamma-, and delta-sarcoglycan function as an interdependent subgroup and that sarcoglycan loss alone is sufficient to produce membrane disruptions and apoptosis independently of dystrophin [PMID:9732288]. Beyond striated muscle, gamma-sarcoglycan assembles into a distinct smooth-muscle sarcoglycan-sarcospan complex with epsilon-, beta-, and delta-sarcoglycan and sarcospan [PMID:10993904]. Its structural role in complex assembly can be substituted by the homolog zeta-sarcoglycan [PMID:16635485]. Correct dosage and membrane targeting are critical: overexpression produces cytoplasmic aggregates and dystrophy [PMID:11287429], and transcription is driven by MyoD-dependent myogenic enhancers [PMID:11179961]. Distinct from its scaffolding role, gamma-sarcoglycan transduces mechanical signals: its intracellular Tyr6 is dispensable for sarcolemmal localization but required for eccentric-contraction-induced ERK1/2 phosphorylation [PMID:20371873], and its loss causes sustained, dysregulated mTOR/p70S6K activation after stretch [PMID:25024843]. Mechanotransduction is mediated through interactions with archvillin, whose mechanically stimulated association with P-ERK1/2 requires gamma-sarcoglycan [PMID:25605665], and with NKCC1 (SLC12A2), whose inhibition blunts strain-induced ERK1/2 signaling [PMID:35065666]. Gamma-sarcoglycan additionally localizes to the sarcoplasmic reticulum [PMID:11259456], binds biglycan as an extracellular ligand and developmental regulator [PMID:16883602], and is subject to N-linked glycosylation [PMID:37929139].","teleology":[{"year":1995,"claim":"Established that gamma-sarcoglycan is genetically required for the integrity of the entire sarcoglycan complex, linking SGCG mutations to muscular dystrophy.","evidence":"Genetic mapping and mutation analysis in SCARMD patients with protein complex assessment","pmids":["7481775"],"confidence":"High","gaps":["Did not define the molecular interactions stabilizing the complex","No mechanism for membrane damage downstream of complex loss"]},{"year":1996,"claim":"Mapped the C-terminal cysteine-rich region as essential for complex stability and demonstrated tight, SDS-resistant biochemical association among sarcoglycans.","evidence":"Mutation analysis of patient biopsies with subunit immunostaining; SDS-resistance co-fractionation of the dystrophin-glycoprotein complex","pmids":["8923014","8641426"],"confidence":"Medium","gaps":["No atomic structure of the interaction interfaces","Stoichiometry of the assembled complex not resolved"]},{"year":1998,"claim":"Showed via genetic knockout that beta/gamma/delta-sarcoglycans form an interdependent unit and that sarcoglycan loss alone causes membrane damage and apoptosis independent of dystrophin.","evidence":"Homologous recombination knockout mouse with Evans blue staining, immunofluorescence, and TUNEL","pmids":["9732288"],"confidence":"High","gaps":["Did not establish the signaling mechanism linking loss to apoptosis","Dystrophin-independent function left mechanistically undefined"]},{"year":2000,"claim":"Extended gamma-sarcoglycan function to smooth muscle, defining a distinct sarcoglycan-sarcospan complex separate from the striated-muscle assembly.","evidence":"Co-immunoprecipitation and biochemical analysis of smooth muscle membranes plus patient tissue","pmids":["10993904"],"confidence":"Medium","gaps":["Functional role of the smooth muscle complex not tested","Tissue-specific assembly determinants unknown"]},{"year":2001,"claim":"Defined the determinants of correct expression and assembly: MyoD-driven myogenic transcription, dosage sensitivity, and SR localization beyond the sarcolemma.","evidence":"Promoter reporter/EMSA assays; transgenic overexpression mouse; confocal and immunoelectron microscopy","pmids":["11179961","11287429","11259456"],"confidence":"Medium","gaps":["SR-specific function of gamma-sarcoglycan not defined","Mechanism of aggregate-induced dystrophy on overexpression unclear"]},{"year":2006,"claim":"Identified biglycan as a direct extracellular ligand and developmental regulator, and showed zeta-sarcoglycan can structurally substitute for gamma-sarcoglycan.","evidence":"Ligand blot overlay, reciprocal Co-IP and chimera mapping; co-transfection/IP of all six sarcoglycans in CHO cells","pmids":["16883602","16635485"],"confidence":"Medium","gaps":["Functional consequence of biglycan binding for signaling not established","Why zeta cannot fully rescue in vivo not addressed"]},{"year":2010,"claim":"Separated gamma-sarcoglycan's localization and signaling functions, showing intracellular Tyr6 is required for mechanically induced ERK1/2 signaling but not membrane targeting.","evidence":"Viral gene transfer of WT and Y6A mutants into gsg-/- muscle with localization and post-eccentric-contraction ERK1/2 readouts","pmids":["20371873"],"confidence":"High","gaps":["Kinase/adaptor acting on Tyr6 not identified","Direct phosphorylation status of Tyr6 not demonstrated"]},{"year":2010,"claim":"Indicated that delta-sarcoglycan stabilizes gamma-sarcoglycan in both T-tubule and SR membranes.","evidence":"Immunoblotting of purified TT and SR fractions from delta-SG knockout mice","pmids":["20638123"],"confidence":"Low","gaps":["Single method (immunoblotting) with no direct interaction experiment for gamma-SG","Does not distinguish stabilization from co-trafficking"]},{"year":2014,"claim":"Demonstrated that gamma-sarcoglycan is required to terminate the mTOR/p70S6K mechanotransduction response, with its loss causing sustained, calcium-independent pathway activation.","evidence":"Cyclic stretch of myotubes/muscles from WT and gamma-SG-null mice with phospho-immunoblotting and rapamycin/calcium-chelation pharmacology","pmids":["25024843"],"confidence":"Medium","gaps":["Molecular link between gamma-SG and mTOR not defined","Rapamycin-resistant S6RP phosphorylation unexplained"]},{"year":2015,"claim":"Identified archvillin as a gamma-sarcoglycan-interacting, mechanically sensitive signaling component bridging the complex to ERK1/2.","evidence":"Yeast two-hybrid screen with in vivo immunofluorescence, rAAV rescue, eccentric contractions, and Co-IP with P-ERK1/2","pmids":["25605665"],"confidence":"Medium","gaps":["Direct binding interface on gamma-sarcoglycan not mapped","Whether archvillin recruitment is Tyr6-dependent untested"]},{"year":2019,"claim":"Provided the first structural characterization of full-length gamma-sarcoglycan as a purified membrane glycoprotein.","evidence":"Recombinant E. coli expression, chemical cleavage, and 15N solution NMR in detergents","pmids":["31682967"],"confidence":"Medium","gaps":["Only preliminary spectra, no resolved structure","Detergent environment may not reflect native bilayer"]},{"year":2022,"claim":"Identified NKCC1 (SLC12A2) as a novel complex-associated partner functionally linked to gamma-sarcoglycan-dependent mechanosignaling.","evidence":"LC-MS/MS of anti-Sgcg sarcolemmal immunoprecipitates with Co-IP, co-localization, and bumetanide inhibition of strain-induced ERK1/2","pmids":["35065666"],"confidence":"Medium","gaps":["Whether the interaction is direct vs complex-mediated unresolved","Single lab; reciprocal endogenous validation limited"]},{"year":2023,"claim":"Reconstituted N-linked glycosylation of gamma-sarcoglycan in a lipid bilayer, confirming the asparagine modification can occur enzymatically in vitro.","evidence":"Nanodisc reconstitution with in vitro oligosaccharyltransferase glycosylation assay, validated by SDS-PAGE and MS","pmids":["37929139"],"confidence":"Medium","gaps":["Functional role of glycosylation in vivo not established","Single in vitro demonstration"]},{"year":null,"claim":"How gamma-sarcoglycan mechanically couples sarcolemmal strain to intracellular ERK1/2 and mTOR/p70S6K signaling at the molecular level remains undefined.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No identified kinase phosphorylating Tyr6","No high-resolution structure of the assembled complex or its signaling interfaces","Direct mechanistic chain from gamma-SG to archvillin/NKCC1 to ERK/mTOR not reconstituted"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[10,11,14]},{"term_id":"GO:0005198","term_label":"structural molecule activity","supporting_discovery_ids":[0,2,3]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[2,3,10]},{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[7,16]}],"pathway":[],"complexes":["sarcoglycan-sarcospan complex","dystrophin-glycoprotein complex"],"partners":["SGCB","SGCD","SGCA","BIGLYCAN","ARCHVILLIN","NKCC1/SLC12A2","SARCOSPAN"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q13326","full_name":"Gamma-sarcoglycan","aliases":["35 kDa dystrophin-associated glycoprotein","35DAG"],"length_aa":291,"mass_kda":32.4,"function":"Component of the sarcoglycan complex, a subcomplex of the dystrophin-glycoprotein complex which forms a link between the F-actin cytoskeleton and the extracellular matrix","subcellular_location":"Cell membrane, sarcolemma; Cytoplasm, cytoskeleton","url":"https://www.uniprot.org/uniprotkb/Q13326/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/SGCG","classification":"Not Classified","n_dependent_lines":2,"n_total_lines":1208,"dependency_fraction":0.0016556291390728477},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/SGCG","total_profiled":1310},"omim":[{"mim_id":"608896","title":"SARCOGLYCAN, GAMMA; SGCG","url":"https://www.omim.org/entry/608896"},{"mim_id":"608113","title":"SARCOGLYCAN, ZETA; SGCZ","url":"https://www.omim.org/entry/608113"},{"mim_id":"608099","title":"MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 3; LGMDR3","url":"https://www.omim.org/entry/608099"},{"mim_id":"607155","title":"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 5; MDDGC5","url":"https://www.omim.org/entry/607155"},{"mim_id":"604286","title":"MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 4; LGMDR4","url":"https://www.omim.org/entry/604286"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Group enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"heart muscle","ntpm":111.2},{"tissue":"skeletal muscle","ntpm":148.0},{"tissue":"tongue","ntpm":134.5}],"url":"https://www.proteinatlas.org/search/SGCG"},"hgnc":{"alias_symbol":["SCARMD2","DAGA4","SCG3","DMDA","TYPE","A4","MGC130048"],"prev_symbol":["DMDA1","MAM","LGMD2C"]},"alphafold":{"accession":"Q13326","domains":[{"cath_id":"-","chopping":"126-162","consensus_level":"medium","plddt":87.0303,"start":126,"end":162},{"cath_id":"-","chopping":"193-247","consensus_level":"medium","plddt":90.3818,"start":193,"end":247},{"cath_id":"-","chopping":"260-291","consensus_level":"medium","plddt":78.4122,"start":260,"end":291},{"cath_id":"1.20.5","chopping":"29-70","consensus_level":"medium","plddt":84.6676,"start":29,"end":70}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q13326","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q13326-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q13326-F1-predicted_aligned_error_v6.png","plddt_mean":80.31},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=SGCG","jax_strain_url":"https://www.jax.org/strain/search?query=SGCG"},"sequence":{"accession":"Q13326","fasta_url":"https://rest.uniprot.org/uniprotkb/Q13326.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q13326/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q13326"}},"corpus_meta":[{"pmid":"7481775","id":"PMC_7481775","title":"Mutations in the dystrophin-associated protein gamma-sarcoglycan in chromosome 13 muscular dystrophy.","date":"1995","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/7481775","citation_count":468,"is_preprint":false},{"pmid":"9732288","id":"PMC_9732288","title":"Gamma-sarcoglycan deficiency leads to muscle membrane defects and apoptosis independent of dystrophin.","date":"1998","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/9732288","citation_count":256,"is_preprint":false},{"pmid":"8923014","id":"PMC_8923014","title":"Mutations that disrupt the carboxyl-terminus of gamma-sarcoglycan cause muscular dystrophy.","date":"1996","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/8923014","citation_count":135,"is_preprint":false},{"pmid":"8968757","id":"PMC_8968757","title":"A founder mutation in the gamma-sarcoglycan gene of gypsies possibly predating their migration out of India.","date":"1996","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/8968757","citation_count":118,"is_preprint":false},{"pmid":"8900232","id":"PMC_8900232","title":"Mild and severe muscular dystrophy caused by a single gamma-sarcoglycan mutation.","date":"1996","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/8900232","citation_count":113,"is_preprint":false},{"pmid":"10933922","id":"PMC_10933922","title":"Rescue of skeletal muscles of gamma-sarcoglycan-deficient mice with adeno-associated virus-mediated gene transfer.","date":"2000","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/10933922","citation_count":80,"is_preprint":false},{"pmid":"9027857","id":"PMC_9027857","title":"Abnormalities in alpha-, beta- and gamma-sarcoglycan in patients with limb-girdle muscular dystrophy.","date":"1996","source":"Neuromuscular disorders : NMD","url":"https://pubmed.ncbi.nlm.nih.gov/9027857","citation_count":67,"is_preprint":false},{"pmid":"22240777","id":"PMC_22240777","title":"A phase I trial of adeno-associated virus serotype 1-γ-sarcoglycan gene therapy for limb girdle muscular dystrophy type 2C.","date":"2012","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/22240777","citation_count":66,"is_preprint":false},{"pmid":"8641426","id":"PMC_8641426","title":"Absence of gamma-sarcoglycan (35 DAG) in autosomal recessive muscular dystrophy linked to chromosome 13q12.","date":"1996","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/8641426","citation_count":54,"is_preprint":false},{"pmid":"10720277","id":"PMC_10720277","title":"Homogeneous phenotype of the gypsy limb-girdle MD with the gamma-sarcoglycan C283Y mutation.","date":"2000","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/10720277","citation_count":52,"is_preprint":false},{"pmid":"11287429","id":"PMC_11287429","title":"Overexpression of gamma-sarcoglycan induces severe muscular dystrophy. Implications for the regulation of Sarcoglycan assembly.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11287429","citation_count":51,"is_preprint":false},{"pmid":"16883602","id":"PMC_16883602","title":"Biglycan binds to alpha- and gamma-sarcoglycan and regulates their expression during development.","date":"2006","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/16883602","citation_count":46,"is_preprint":false},{"pmid":"10993904","id":"PMC_10993904","title":"Expression of gamma -sarcoglycan in smooth muscle and its interaction with the smooth muscle sarcoglycan-sarcospan complex.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10993904","citation_count":43,"is_preprint":false},{"pmid":"12609501","id":"PMC_12609501","title":"Pathological analysis of muscle hypertrophy and degeneration in muscular dystrophy in gamma-sarcoglycan-deficient mice.","date":"2003","source":"Neuromuscular disorders : NMD","url":"https://pubmed.ncbi.nlm.nih.gov/12609501","citation_count":31,"is_preprint":false},{"pmid":"16635485","id":"PMC_16635485","title":"Zeta-sarcoglycan is a functional homologue of gamma-sarcoglycan in the formation of the sarcoglycan complex.","date":"2006","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/16635485","citation_count":25,"is_preprint":false},{"pmid":"9673983","id":"PMC_9673983","title":"A novel gamma-sarcoglycan mutation causing childhood onset, slowly progressive limb girdle muscular dystrophy.","date":"1998","source":"Neuromuscular disorders : NMD","url":"https://pubmed.ncbi.nlm.nih.gov/9673983","citation_count":23,"is_preprint":false},{"pmid":"25605665","id":"PMC_25605665","title":"Gamma-sarcoglycan is required for the response of archvillin to mechanical stimulation in skeletal muscle.","date":"2015","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25605665","citation_count":20,"is_preprint":false},{"pmid":"15769854","id":"PMC_15769854","title":"gamma-Sarcoglycan deficiency increases cell contractility, apoptosis and MAPK pathway activation but does not affect adhesion.","date":"2005","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/15769854","citation_count":20,"is_preprint":false},{"pmid":"11179961","id":"PMC_11179961","title":"Identification of myogenesis-dependent transcriptional enhancers in promoter region of mouse gamma-sarcoglycan gene.","date":"2001","source":"European journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11179961","citation_count":20,"is_preprint":false},{"pmid":"9705137","id":"PMC_9705137","title":"Different manners of sarcoglycan expression in genetically proven alpha-sarcoglycan deficiency and gamma-sarcoglycan deficiency.","date":"1998","source":"Acta neuropathologica","url":"https://pubmed.ncbi.nlm.nih.gov/9705137","citation_count":19,"is_preprint":false},{"pmid":"9781048","id":"PMC_9781048","title":"Severe limb girdle muscular dystrophy in Spanish gypsies: further evidence for a founder mutation in the gamma-sarcoglycan gene.","date":"1998","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/9781048","citation_count":18,"is_preprint":false},{"pmid":"26908621","id":"PMC_26908621","title":"Collagen VI deficiency reduces muscle pathology, but does not improve muscle function, in the γ-sarcoglycan-null mouse.","date":"2016","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26908621","citation_count":17,"is_preprint":false},{"pmid":"25024843","id":"PMC_25024843","title":"Absence of γ-sarcoglycan alters the response of p70S6 kinase to mechanical perturbation in murine skeletal muscle.","date":"2014","source":"Skeletal muscle","url":"https://pubmed.ncbi.nlm.nih.gov/25024843","citation_count":15,"is_preprint":false},{"pmid":"11259456","id":"PMC_11259456","title":"delta- and gamma-Sarcoglycan localization in the sarcoplasmic reticulum of skeletal muscle.","date":"2001","source":"The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society","url":"https://pubmed.ncbi.nlm.nih.gov/11259456","citation_count":14,"is_preprint":false},{"pmid":"36816759","id":"PMC_36816759","title":"Systemic γ-sarcoglycan AAV gene transfer results in dose-dependent correction of muscle deficits in the LGMD 2C/R5 mouse model.","date":"2023","source":"Molecular therapy. Methods & clinical development","url":"https://pubmed.ncbi.nlm.nih.gov/36816759","citation_count":13,"is_preprint":false},{"pmid":"20371873","id":"PMC_20371873","title":"Restoration of gamma-sarcoglycan localization and mechanical signal transduction are independent in murine skeletal muscle.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20371873","citation_count":13,"is_preprint":false},{"pmid":"11322951","id":"PMC_11322951","title":"Analysis of the spatial, temporal and tissue-specific transcription of gamma-sarcoglycan gene using a transgenic mouse.","date":"2001","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/11322951","citation_count":11,"is_preprint":false},{"pmid":"27759885","id":"PMC_27759885","title":"γ-sarcoglycan and dystrophin mutation spectrum in an Algerian cohort.","date":"2017","source":"Muscle & nerve","url":"https://pubmed.ncbi.nlm.nih.gov/27759885","citation_count":11,"is_preprint":false},{"pmid":"10874299","id":"PMC_10874299","title":"Private beta- and gamma-sarcoglycan gene mutations: evidence of a founder effect in Northern Italy.","date":"2000","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/10874299","citation_count":11,"is_preprint":false},{"pmid":"24742800","id":"PMC_24742800","title":"Sarcolemmal alpha and gamma sarcoglycan protein deficiencies in Turkish siblings with a novel missense mutation in the alpha sarcoglycan gene.","date":"2014","source":"Pediatric neurology","url":"https://pubmed.ncbi.nlm.nih.gov/24742800","citation_count":11,"is_preprint":false},{"pmid":"20638123","id":"PMC_20638123","title":"Altered calcium pump and secondary deficiency of gamma-sarcoglycan and microspan in sarcoplasmic reticulum membranes isolated from delta-sarcoglycan knockout mice.","date":"2010","source":"Cell calcium","url":"https://pubmed.ncbi.nlm.nih.gov/20638123","citation_count":10,"is_preprint":false},{"pmid":"10447257","id":"PMC_10447257","title":"C283Y mutation and other C-terminal nucleotide changes in the gamma-sarcoglycan gene in the Bulgarian Gypsy population.","date":"1999","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/10447257","citation_count":10,"is_preprint":false},{"pmid":"14960875","id":"PMC_14960875","title":"Screening for C283Y gamma-sarcoglycan mutation in a high-risk group of Bulgarian Gypsies: evidence for a geographical localization and a non-random distribution among Gypsy subgroups.","date":"2002","source":"Community genetics","url":"https://pubmed.ncbi.nlm.nih.gov/14960875","citation_count":9,"is_preprint":false},{"pmid":"15479193","id":"PMC_15479193","title":"C283Y gamma-sarcoglycan gene mutation in the Bulgarian Roma (Gypsy) population: prevalence study and carrier screening in a high-risk community.","date":"2004","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15479193","citation_count":7,"is_preprint":false},{"pmid":"31682967","id":"PMC_31682967","title":"Expression, purification, and structural analysis of the full-length human integral membrane protein γ-sarcoglycan.","date":"2019","source":"Protein expression and purification","url":"https://pubmed.ncbi.nlm.nih.gov/31682967","citation_count":5,"is_preprint":false},{"pmid":"35065666","id":"PMC_35065666","title":"Novel γ-sarcoglycan interactors in murine muscle membranes.","date":"2022","source":"Skeletal muscle","url":"https://pubmed.ncbi.nlm.nih.gov/35065666","citation_count":3,"is_preprint":false},{"pmid":"25050186","id":"PMC_25050186","title":"Concomitant alpha- and gamma-sarcoglycan deficiencies in a Turkish boy with a novel deletion in the alpha-sarcoglycan gene.","date":"2014","source":"Case reports in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25050186","citation_count":3,"is_preprint":false},{"pmid":"12040521","id":"PMC_12040521","title":"[Muscular dystrophy due to a deficit of gamma-sarcoglycan. A report of three patients with the Delta-521t mutation].","date":"2002","source":"Revista de neurologia","url":"https://pubmed.ncbi.nlm.nih.gov/12040521","citation_count":3,"is_preprint":false},{"pmid":"37929139","id":"PMC_37929139","title":"In Vitro Glycosylation of the Membrane Protein γ-Sarcoglycan in Nanodiscs.","date":"2023","source":"ACS omega","url":"https://pubmed.ncbi.nlm.nih.gov/37929139","citation_count":2,"is_preprint":false},{"pmid":"11856878","id":"PMC_11856878","title":"Characterization and chromosome assignment of the canine gamma-sarcoglycan gene (SGCG) to CFA 25q21-->q23.","date":"2001","source":"Cytogenetics and cell genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11856878","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"sonnet_model":"claude-sonnet-4-6","sonnet_input_tokens":20511,"sonnet_output_tokens":4230,"sonnet_usd":0.125,"sonnet_elapsed_seconds":71.8,"stage1_stop_reason":"end_turn"},"stage2":{"opus_model":"claude-opus-4-8","opus_input_tokens":12334,"opus_output_tokens":4216,"opus_usd":0.1671,"opus_elapsed_seconds":44.6,"stage2_stop_reason":"end_turn"},"total_usd":0.2921},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1995,\n      \"finding\": \"Mutations in gamma-sarcoglycan (SGCG) not only abolish gamma-sarcoglycan but also disrupt the integrity of the entire sarcoglycan complex, establishing that gamma-sarcoglycan is required for complex integrity.\",\n      \"method\": \"Genetic mapping and mutation analysis in SCARMD patients combined with protein complex assessment\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — foundational genetic and biochemical finding replicated across multiple subsequent studies\",\n      \"pmids\": [\"7481775\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Frameshifting mutations disrupting the distal carboxyl-terminus of gamma-sarcoglycan result in complete absence of both gamma- and beta-sarcoglycan, demonstrating that the C-terminal region (which contains EGF-like cysteine-rich sequences) is essential for stability of the sarcoglycan complex.\",\n      \"method\": \"Mutation analysis of patient muscle biopsies combined with immunostaining for sarcoglycan subunits\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic/biochemical evidence from multiple patients, single lab\",\n      \"pmids\": [\"8923014\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Alpha-, beta-, and gamma-sarcoglycan constitute a tightly associated sarcolemmal complex that cannot be disrupted by SDS treatment, demonstrating their strong biochemical interdependence at the sarcolemma.\",\n      \"method\": \"Immunofluorescence, Western blotting, and SDS-resistance co-fractionation of the dystrophin-glycoprotein complex from skeletal muscle\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct biochemical fractionation in patient and control muscle, single lab\",\n      \"pmids\": [\"8641426\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Genetic knockout of gamma-sarcoglycan in mice causes secondary reduction of beta- and delta-sarcoglycan with partial retention of alpha- and epsilon-sarcoglycan, indicating that beta-, gamma-, and delta-sarcoglycan function as a unit. Membrane disruptions and apoptosis occurred independently of dystrophin loss, demonstrating that sarcoglycan loss is itself sufficient to cause membrane defects.\",\n      \"method\": \"Homologous recombination knockout mouse; Evans blue dye vital staining; immunofluorescence; TUNEL apoptosis assay\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO with multiple orthogonal readouts, widely replicated\",\n      \"pmids\": [\"9732288\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Gamma-sarcoglycan is expressed in smooth muscle and associates with epsilon-, beta-, and delta-sarcoglycans and sarcospan to form the smooth muscle sarcoglycan-sarcospan complex, distinct from the striated muscle complex.\",\n      \"method\": \"Immunoblotting, co-immunoprecipitation/biochemical analysis of smooth muscle membranes, smooth muscle cell culture, and analysis of animal models and a patient with gamma-sarcoglycanopathy\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — biochemical co-fractionation and patient tissue analysis, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"10993904\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Overexpression of gamma-sarcoglycan in mouse muscle leads to cytoplasmic aggregates that prevent normal membrane targeting, upregulation of alpha- and beta-sarcoglycan, and severe muscular dystrophy — demonstrating that proper dosage and membrane localization of gamma-sarcoglycan are critical for correct sarcoglycan complex assembly.\",\n      \"method\": \"Transgenic mouse overexpression under muscle creatine kinase promoter; histology; immunofluorescence; Western blotting\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — transgenic mouse model with multiple readouts, single lab\",\n      \"pmids\": [\"11287429\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"The gamma-sarcoglycan promoter contains a basal promoter region and two myogenesis-dependent enhancer regions; A/T-rich and E-box elements in the upstream enhancer are essential for activation after myotube formation, and MyoD acts as a trans-activator of gamma-sarcoglycan transcription.\",\n      \"method\": \"Reporter gene constructs with promoter deletions in C2C12 cells; co-transfection with MyoD expression vectors in 10T1/2 fibroblasts; electrophoretic mobility shift assay for binding protein identification\",\n      \"journal\": \"European journal of biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter deletion and co-transfection assays, single lab, multiple constructs tested\",\n      \"pmids\": [\"11179961\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Delta- and gamma-sarcoglycans localize not only to the sarcolemma but also to the sarcoplasmic reticulum in skeletal muscle: delta-sarcoglycan is found in terminal cisternae, while gamma-sarcoglycan is found in both terminal cisternae and longitudinal SR over I-bands, suggesting functions independent of the dystrophin complex in the SR.\",\n      \"method\": \"Confocal microscopy and immunoelectron microscopy with subcellular marker co-labeling in rat and mouse skeletal muscle\",\n      \"journal\": \"The journal of histochemistry and cytochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — immunoelectron microscopy with co-localization controls, single lab\",\n      \"pmids\": [\"11259456\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Biglycan physically binds to gamma-sarcoglycan (as well as alpha-sarcoglycan) via distinct sites on its polypeptide core, and is a component of the dystrophin glycoprotein complex isolated from skeletal muscle membranes. In biglycan-null mice, gamma-sarcoglycan expression is selectively reduced at early developmental stages (P14–P21), establishing biglycan as a ligand and developmental regulator of gamma-sarcoglycan.\",\n      \"method\": \"Ligand blot overlay, co-immunoprecipitation, biglycan-decorin chimeras, biochemical fractionation of skeletal muscle membranes, immunohistochemistry and Western blotting in biglycan-null mice\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP and ligand blot with chimera mapping, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"16883602\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Zeta-sarcoglycan can substitute for gamma-sarcoglycan in forming a sarcoglycan complex (alpha-beta-zeta-delta), demonstrating that gamma-sarcoglycan's structural role in complex formation can be fulfilled by its homolog zeta-sarcoglycan.\",\n      \"method\": \"Co-transfection of expression vectors for all six sarcoglycans and dystroglycan into CHO cells followed by immunoprecipitation analysis\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-immunoprecipitation in transfected cells with multiple sarcoglycan combinations, single lab\",\n      \"pmids\": [\"16635485\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Tyrosine 6 (Tyr6) in the intracellular domain of gamma-sarcoglycan is not required for sarcolemmal localization, but is required for normal ERK1/2 phosphorylation signaling after eccentric contractions — demonstrating that localization and mechanical signal transduction are molecularly separable functions of gamma-sarcoglycan.\",\n      \"method\": \"Viral-mediated gene transfer of wild-type and Y6A mutant gamma-sarcoglycan into gsg-/- mouse muscle; immunofluorescence for localization; immunoblotting for ERK1/2 phosphorylation after eccentric contractions\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — site-directed mutagenesis with in vivo functional readout (two orthogonal assays), single lab but rigorous\",\n      \"pmids\": [\"20371873\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Loss of gamma-sarcoglycan elevates basal p70S6K activation in skeletal muscle in a calcium-independent manner and causes sustained (rather than transient) p70S6K activation after stretch; rapamycin blocks p70S6K but cannot normalize downstream S6RP phosphorylation in gamma-SG-null muscle, indicating gamma-sarcoglycan is required for proper inactivation of the mTOR/p70S6K mechanotransduction pathway.\",\n      \"method\": \"Cyclic passive stretch of C2C12 myotubes, primary cultures and isolated muscles from C57 and gamma-SG-null mice; immunoblotting for phosphorylated signaling proteins; rapamycin and calcium-chelation pharmacological experiments\",\n      \"journal\": \"Skeletal muscle\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple cell and tissue preparations with pharmacological validation, single lab\",\n      \"pmids\": [\"25024843\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Gamma-sarcoglycan interacts with the muscle-specific protein archvillin (identified by yeast two-hybrid), and loss of gamma-sarcoglycan causes archvillin upregulation and delocalization at the sarcolemma as well as ablation of the mechanically stimulated archvillin–P-ERK1/2 association, positioning archvillin as a mechanically sensitive signaling component downstream of gamma-sarcoglycan.\",\n      \"method\": \"Yeast two-hybrid screen; immunofluorescence and Western blotting in gsg-/- and mdx mouse muscle; rAAV rescue experiments; in situ eccentric contractions with P-ERK1/2 nuclear activation analysis; co-immunoprecipitation of archvillin with P-ERK1/2\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — yeast two-hybrid plus multiple orthogonal in vivo validations, single lab\",\n      \"pmids\": [\"25605665\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Full-length recombinant gamma-sarcoglycan (SGCG) was expressed, purified, and subjected to solution NMR spectroscopy in detergent environments, yielding the first NMR spectra of the full-length membrane glycoprotein and providing initial structural characterization.\",\n      \"method\": \"Recombinant expression in E. coli inclusion bodies using TrpΔLE fusion; chemical cleavage; size-exclusion chromatography; SDS-PAGE; mass spectrometry; 15N-labeled solution NMR spectroscopy\",\n      \"journal\": \"Protein expression and purification\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — first structural characterization by NMR, single lab, preliminary spectra only\",\n      \"pmids\": [\"31682967\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Proteomic analysis of gamma-sarcoglycan immunoprecipitates from sarcolemmal fractions identified NKCC1 (SLC12A2) as a novel gamma-sarcoglycan complex-associated protein; NKCC1 co-localizes with gamma-sarcoglycan upon co-expression in RH30 cells and co-immunoprecipitates via its cytosolic domains. Pharmacological inhibition of NKCC1 with bumetanide reduces strain-induced ERK1/2 phosphorylation in isolated muscles, linking NKCC1 to gamma-sarcoglycan-dependent mechanosignaling.\",\n      \"method\": \"LC-MS/MS proteomics of anti-Sgcg immunoprecipitates from enriched sarcolemmal fractions; co-expression and co-immunoprecipitation in RH30 rhabdomyosarcoma cells; immunofluorescence co-localization; bumetanide pharmacological inhibition with ERK1/2 phosphorylation readout in isolated muscles\",\n      \"journal\": \"Skeletal muscle\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — MS proteomics validated by Co-IP and functional pharmacological experiment, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"35065666\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Gamma-sarcoglycan incorporated into nanodiscs can undergo N-linked glycosylation in vitro by enzymatic transfer of sugar to an asparagine residue, demonstrating that this post-translational modification can be reconstituted in a lipid bilayer environment.\",\n      \"method\": \"Nanodisc reconstitution with long-chain lipids and membrane scaffold proteins; in vitro N-linked glycosylation assay with oligosaccharyltransferase; SDS-PAGE and mass spectrometry validation\",\n      \"journal\": \"ACS omega\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — in vitro reconstitution of glycosylation, single lab, first demonstration\",\n      \"pmids\": [\"37929139\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"In delta-sarcoglycan knockout mice, gamma-sarcoglycan expression is secondarily reduced in both transverse tubule and sarcoplasmic reticulum membranes, demonstrating that delta-sarcoglycan stabilizes gamma-sarcoglycan in these intracellular membrane compartments.\",\n      \"method\": \"Immunoblotting of purified TT and SR membrane fractions from wild-type and delta-SG knockout mice\",\n      \"journal\": \"Cell calcium\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, single method (immunoblotting of fractionated membranes) with no direct interaction experiment for gamma-SG\",\n      \"pmids\": [\"20638123\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"Gamma-sarcoglycan (SGCG) is a transmembrane component of the dystrophin-associated glycoprotein complex that, together with alpha-, beta-, and delta-sarcoglycans, forms a sarcolemmal heterotetrameric complex essential for membrane integrity in skeletal, cardiac, and smooth muscle; loss of gamma-sarcoglycan causes secondary destabilization of the entire sarcoglycan complex, membrane disruptions, apoptosis, and aberrant mechanotransduction signaling (including dysregulated ERK1/2 and mTOR/p70S6K pathways) independently of dystrophin, with its intracellular Tyr6 required for mechanical signal transduction but not for sarcolemmal localization, and its extracellular domain subject to N-linked glycosylation; gamma-sarcoglycan also localizes to the sarcoplasmic reticulum and interacts with biglycan and NKCC1 as extracellular and signaling partners, respectively.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"Gamma-sarcoglycan (SGCG) is a transmembrane component of the sarcolemmal sarcoglycan complex whose loss causes limb-girdle muscular dystrophy through destabilization of the complex and direct membrane damage [#0, #3]. Mutation analysis in patients first established that loss of gamma-sarcoglycan collapses the integrity of the entire sarcoglycan complex, with the cysteine-rich C-terminus being essential for complex stability [#0, #1]; alpha-, beta-, and gamma-sarcoglycan form a tightly associated, SDS-resistant sarcolemmal unit [#2]. Genetic knockout in mice demonstrated that beta-, gamma-, and delta-sarcoglycan function as an interdependent subgroup and that sarcoglycan loss alone is sufficient to produce membrane disruptions and apoptosis independently of dystrophin [#3]. Beyond striated muscle, gamma-sarcoglycan assembles into a distinct smooth-muscle sarcoglycan-sarcospan complex with epsilon-, beta-, and delta-sarcoglycan and sarcospan [#4]. Its structural role in complex assembly can be substituted by the homolog zeta-sarcoglycan [#9]. Correct dosage and membrane targeting are critical: overexpression produces cytoplasmic aggregates and dystrophy [#5], and transcription is driven by MyoD-dependent myogenic enhancers [#6]. Distinct from its scaffolding role, gamma-sarcoglycan transduces mechanical signals: its intracellular Tyr6 is dispensable for sarcolemmal localization but required for eccentric-contraction-induced ERK1/2 phosphorylation [#10], and its loss causes sustained, dysregulated mTOR/p70S6K activation after stretch [#11]. Mechanotransduction is mediated through interactions with archvillin, whose mechanically stimulated association with P-ERK1/2 requires gamma-sarcoglycan [#12], and with NKCC1 (SLC12A2), whose inhibition blunts strain-induced ERK1/2 signaling [#14]. Gamma-sarcoglycan additionally localizes to the sarcoplasmic reticulum [#7], binds biglycan as an extracellular ligand and developmental regulator [#8], and is subject to N-linked glycosylation [#15].\",\n  \"teleology\": [\n    {\n      \"year\": 1995,\n      \"claim\": \"Established that gamma-sarcoglycan is genetically required for the integrity of the entire sarcoglycan complex, linking SGCG mutations to muscular dystrophy.\",\n      \"evidence\": \"Genetic mapping and mutation analysis in SCARMD patients with protein complex assessment\",\n      \"pmids\": [\"7481775\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the molecular interactions stabilizing the complex\", \"No mechanism for membrane damage downstream of complex loss\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Mapped the C-terminal cysteine-rich region as essential for complex stability and demonstrated tight, SDS-resistant biochemical association among sarcoglycans.\",\n      \"evidence\": \"Mutation analysis of patient biopsies with subunit immunostaining; SDS-resistance co-fractionation of the dystrophin-glycoprotein complex\",\n      \"pmids\": [\"8923014\", \"8641426\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No atomic structure of the interaction interfaces\", \"Stoichiometry of the assembled complex not resolved\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Showed via genetic knockout that beta/gamma/delta-sarcoglycans form an interdependent unit and that sarcoglycan loss alone causes membrane damage and apoptosis independent of dystrophin.\",\n      \"evidence\": \"Homologous recombination knockout mouse with Evans blue staining, immunofluorescence, and TUNEL\",\n      \"pmids\": [\"9732288\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish the signaling mechanism linking loss to apoptosis\", \"Dystrophin-independent function left mechanistically undefined\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Extended gamma-sarcoglycan function to smooth muscle, defining a distinct sarcoglycan-sarcospan complex separate from the striated-muscle assembly.\",\n      \"evidence\": \"Co-immunoprecipitation and biochemical analysis of smooth muscle membranes plus patient tissue\",\n      \"pmids\": [\"10993904\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional role of the smooth muscle complex not tested\", \"Tissue-specific assembly determinants unknown\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Defined the determinants of correct expression and assembly: MyoD-driven myogenic transcription, dosage sensitivity, and SR localization beyond the sarcolemma.\",\n      \"evidence\": \"Promoter reporter/EMSA assays; transgenic overexpression mouse; confocal and immunoelectron microscopy\",\n      \"pmids\": [\"11179961\", \"11287429\", \"11259456\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"SR-specific function of gamma-sarcoglycan not defined\", \"Mechanism of aggregate-induced dystrophy on overexpression unclear\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Identified biglycan as a direct extracellular ligand and developmental regulator, and showed zeta-sarcoglycan can structurally substitute for gamma-sarcoglycan.\",\n      \"evidence\": \"Ligand blot overlay, reciprocal Co-IP and chimera mapping; co-transfection/IP of all six sarcoglycans in CHO cells\",\n      \"pmids\": [\"16883602\", \"16635485\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of biglycan binding for signaling not established\", \"Why zeta cannot fully rescue in vivo not addressed\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Separated gamma-sarcoglycan's localization and signaling functions, showing intracellular Tyr6 is required for mechanically induced ERK1/2 signaling but not membrane targeting.\",\n      \"evidence\": \"Viral gene transfer of WT and Y6A mutants into gsg-/- muscle with localization and post-eccentric-contraction ERK1/2 readouts\",\n      \"pmids\": [\"20371873\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Kinase/adaptor acting on Tyr6 not identified\", \"Direct phosphorylation status of Tyr6 not demonstrated\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Indicated that delta-sarcoglycan stabilizes gamma-sarcoglycan in both T-tubule and SR membranes.\",\n      \"evidence\": \"Immunoblotting of purified TT and SR fractions from delta-SG knockout mice\",\n      \"pmids\": [\"20638123\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Single method (immunoblotting) with no direct interaction experiment for gamma-SG\", \"Does not distinguish stabilization from co-trafficking\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Demonstrated that gamma-sarcoglycan is required to terminate the mTOR/p70S6K mechanotransduction response, with its loss causing sustained, calcium-independent pathway activation.\",\n      \"evidence\": \"Cyclic stretch of myotubes/muscles from WT and gamma-SG-null mice with phospho-immunoblotting and rapamycin/calcium-chelation pharmacology\",\n      \"pmids\": [\"25024843\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular link between gamma-SG and mTOR not defined\", \"Rapamycin-resistant S6RP phosphorylation unexplained\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identified archvillin as a gamma-sarcoglycan-interacting, mechanically sensitive signaling component bridging the complex to ERK1/2.\",\n      \"evidence\": \"Yeast two-hybrid screen with in vivo immunofluorescence, rAAV rescue, eccentric contractions, and Co-IP with P-ERK1/2\",\n      \"pmids\": [\"25605665\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct binding interface on gamma-sarcoglycan not mapped\", \"Whether archvillin recruitment is Tyr6-dependent untested\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Provided the first structural characterization of full-length gamma-sarcoglycan as a purified membrane glycoprotein.\",\n      \"evidence\": \"Recombinant E. coli expression, chemical cleavage, and 15N solution NMR in detergents\",\n      \"pmids\": [\"31682967\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Only preliminary spectra, no resolved structure\", \"Detergent environment may not reflect native bilayer\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Identified NKCC1 (SLC12A2) as a novel complex-associated partner functionally linked to gamma-sarcoglycan-dependent mechanosignaling.\",\n      \"evidence\": \"LC-MS/MS of anti-Sgcg sarcolemmal immunoprecipitates with Co-IP, co-localization, and bumetanide inhibition of strain-induced ERK1/2\",\n      \"pmids\": [\"35065666\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether the interaction is direct vs complex-mediated unresolved\", \"Single lab; reciprocal endogenous validation limited\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Reconstituted N-linked glycosylation of gamma-sarcoglycan in a lipid bilayer, confirming the asparagine modification can occur enzymatically in vitro.\",\n      \"evidence\": \"Nanodisc reconstitution with in vitro oligosaccharyltransferase glycosylation assay, validated by SDS-PAGE and MS\",\n      \"pmids\": [\"37929139\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional role of glycosylation in vivo not established\", \"Single in vitro demonstration\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How gamma-sarcoglycan mechanically couples sarcolemmal strain to intracellular ERK1/2 and mTOR/p70S6K signaling at the molecular level remains undefined.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No identified kinase phosphorylating Tyr6\", \"No high-resolution structure of the assembled complex or its signaling interfaces\", \"Direct mechanistic chain from gamma-SG to archvillin/NKCC1 to ERK/mTOR not reconstituted\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [10, 11, 14]},\n      {\"term_id\": \"GO:0005198\", \"supporting_discovery_ids\": [0, 2, 3]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [2, 3, 10]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [7, 16]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0008953854\", \"supporting_discovery_ids\": []}\n    ],\n    \"complexes\": [\n      \"sarcoglycan-sarcospan complex\",\n      \"dystrophin-glycoprotein complex\"\n    ],\n    \"partners\": [\n      \"SGCB\",\n      \"SGCD\",\n      \"SGCA\",\n      \"biglycan\",\n      \"archvillin\",\n      \"NKCC1/SLC12A2\",\n      \"sarcospan\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win"}}